SCHEMBL2660778

SCHEMBL2660778

COc1ccc(CN2Cc3nc4c(-c5cccnc5F)cccc4c(N)c3C2=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.40
▸ KDM4E B2RXH2 3/20 0.39
▸ HKDC1 Q2TB90 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ APP P05067 2/20 0.38
▸ SNCA P37840 2/20 0.38
▸ IDH1 O75874 1/20 0.38
▸ BRD4 O60885 1/20 0.38
▸ THRB P10828 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ CTSD P07339 2/20 0.37
▸ BACE1 P56817 2/20 0.37
▸ BACE2 Q9Y5Z0 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ PDE10A Q9Y233 2/20 0.35
▸ CASP3 P42574 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2655786 0.90 KDM4E (0.40) MAPTKDM4EHKDC1MEN1KMT2A
SCHEMBL2661670 0.89 KDM4E (0.39) MAPTKDM4EMEN1KMT2AIDH1
SCHEMBL2661184 0.88 KDM4E (0.39) KDM4EMEN1KMT2AIDH1LMNA
SCHEMBL2656179 0.85 LMNA (0.39) MAPTKDM4EMEN1KMT2AIDH1
SCHEMBL2660724 0.85 MAPT (0.39) MAPTKDM4EMEN1KMT2ALMNA
SCHEMBL2661180 0.85 PDE5A (0.37) MAPTKDM4EMEN1KMT2AIDH1
SCHEMBL2661041 0.85 LMNA (0.38) MAPTKDM4EMEN1KMT2ALMNA
SCHEMBL2661185 0.85 GABRG2 (0.39) MAPTKDM4ELMNAHTTNPSR1
SCHEMBL2661373 0.84 GABRG2 (0.43) KDM4EMEN1KMT2AIDH1LMNA
SCHEMBL2658694 0.84 GABRA1 (0.43) KDM4EMEN1KMT2ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF MAPT 4/4885KDM4E 2357/4885HKDC1 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback